Pfizer's $7.7B cost-savings plan is boosting margins and EPS, offsetting COVID revenue declines and patent cliff concerns. Core business is growing 12% ex-COVID, with strength in oncology, vaccines, and internal medicine, plus a robust R&D pipeline. Major patent expirations threaten $15B+ in annual revenue by 2028, but Pfizer is aggressively pursuing pipeline and acquisition strategies.
Graham All Star Value (GASV) strategy identifies top dividend 'dogs' offering high yield and fair pricing, using YCharts' large cap value and Ben Graham screens. Analyst projections suggest the top ten GASV stocks could deliver average net gains of 27.55% by July 2026, with moderate risk. Sixteen of the twenty-one lowest-priced, 'safer' GASV dividend stocks are currently buyable, with dividends...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1) for active immunization to prevent COVID-...
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
A study published on 29 June 2025 in international peer reviewed medical journal Expert Opinion on Drug Safety by Frey et al. has found that use of Pfizer's Depo-Provera (DMPA) for more than one year is associated with a 3.5-fold increased risk of developing an intracranial meningioma, a type of brain tumour, compared with the use of certain combined birth control pills1.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio's SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio's proprietary CLF2 platform. This agreement solidifies Pfizer at ...
The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one corner while forgetting others, creating a gap and massive opportunity for rotation into some of these forgotten names that still carry greatly attractive fundamental profiles.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.